Search

Linked Articles: Kruger. Br J Dermatol 2020; DOI: 10.1111/bjd.18691. Garcia‐Souto et al. Br J Dermatol 2019; 181:e35. [ABSTRACT FROM AUTHOR]

A 77-year-old man with no relevant medical history except for prostate carcinoma presented with asymptomatic hyperpigmented linear lesions on the left forearm that appeared after having undergone a diagnostic bone scintigraphy with technetium-99m diphosphonate. Interestingly, the patient admitted that the lesions appeared a few days after the bone scintigraphy, matching on location with the radiopharmaceutical administration site. In conclusion, we report a remarkable skin reaction following SP 99m sp Tc diphosphonate administration manifesting with prominent linear lesions following the distribution of veins. [Extracted from the article]

Competing Interests: There are no conflicts of interest.

The term craniofacial hyperhidrosis (HH) refers to HH that affects the face and/or scalp. Few studies have focused on this specific location, and even fewer distinguish between the two areas. Our study aims are to describe the clinical characteristics of patients with craniofacial HH, specifying whether the condition affects the scalp, face or both, and to compare these cases with those recorded at other locations. As secondary objectives, we determine the effectiveness and adverse effects of oral oxybutynin (OOx), and assess patients' adherence to treatment. This prospective observational study was carried out with respect to the period 2007-2019. All patients diagnosed with HH of the scalp and/or face and who were treated with OOx at our HH unit were included in the study group. Of 292 patients treated with OOx, 97 (33.2%) had craniofacial HH. Of these, 4 (4.1%) presented HH exclusively on the scalp, 56 (57.7%) exclusively on the face and 37 (38.1%) in both locations. The patients in the latter category (compared with those with exclusively facial HH) were significantly older than the others, had a later onset of HH, a greater frequency of secondary HH, less simultaneous involvement of the classical areas of primary focal HH (the palms, soles, and armpits) and greater generalized HH and of the trunk. No significant differences were observed between the three locations (face, scalp, or both) regarding the efficacy and side effects of OOx. The patients with exclusively facial HH presented greater adherence to treatment., (© 2020 Wiley Periodicals LLC.)

The condition of most patients with hyperhidrosis (HH) is known to worsen with increased temperature. However, most prior studies of oral glycopyrrolate (OGly) for the treatment of HH have assumed a stable treatment protocol, without taking into account seasonal variations in temperature. The main aim of this study is to evaluate the outcomes derived from performing a seasonal adjustment of the dose of OGly for patients with HH. A prospective study of patients who began OGly for HH, and maintained treatment for at least 1 year, was performed. All patients had experienced treatment failure with oral oxybutynin. All were recommended to vary the dose of medication according to the time of year. Of the 35 patients included in the study, 20 (57.14%) varied the dose. Those with palmar and plantar HH had a greater propensity to do so. The patients who varied the dose according to the time of year were significantly more likely to report an "Excellent" response after 12 months of treatment. The frequency of adverse effects was 71.4% with no significant differences among the study groups. However, there was a significantly higher proportion of adverse effects other than oral xerosis in the group that did not vary the dose., (© 2020 Wiley Periodicals LLC.)

Competing Interests: There are no conflicts of interest.